At the time of writing, Kymera Therapeutics Inc [KYMR] stock is trading at $49.79, up 1.55%. An important factor to consider is whether the stock is rising or falling in short-term value. The KYMR shares have gain 8.05% over the last week, with a monthly amount glided 2.55%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Wolfe Research upgraded its rating to Outperform on August 26, 2024, and kept the price target unchanged to $65. On April 22, 2024, Oppenheimer initiated with a Outperform rating and assigned a price target of $53 on the stock. Wolfe Research started tracking the stock assigning a Peer Perform rating. JP Morgan upgraded its rating to a Overweight. BofA Securities downgraded its rating to Neutral for this stock on January 03, 2024, and downed its price target to $30. In a note dated December 19, 2023, Wells Fargo downgraded an Equal Weight rating on this stock but restated the target price of $26.
For the past year, the stock price of Kymera Therapeutics Inc fluctuated between $9.60 and $50.69. Currently, Wall Street analysts expect the stock to reach $51.1 within the next 12 months. Kymera Therapeutics Inc [NASDAQ: KYMR] shares were valued at $49.79 at the most recent close of the market. An investor can expect a potential return of 2.63% based on the average KYMR price forecast.
Analyzing the KYMR fundamentals
According to Kymera Therapeutics Inc [NASDAQ:KYMR], the company’s sales were 88.55M for trailing twelve months, which represents an 55.33% jump. Gross Profit Margin for this corporation currently stands at 0.94% with Operating Profit Margin at -2.04%, Pretax Profit Margin comes in at -1.78%, and Net Profit Margin reading is -1.78%. To continue investigating profitability, this company’s Return on Assets is posted at -0.19, Equity is -0.29 and Total Capital is -0.24. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 48.47 points at the first support level, and at 47.16 for the second support level. However, for the 1st resistance point, the stock is sitting at 50.68, and for the 2nd resistance point, it is at 51.57.
Ratios To Look Out For
It is important to note that Kymera Therapeutics Inc [NASDAQ:KYMR] has a current ratio of 8.45. On the other hand, the Quick Ratio is 8.45, and the Cash Ratio is 1.09. Considering the valuation of this stock, the price to sales ratio is 35.85, the price to book ratio is 4.48.
Transactions by insiders
Recent insider trading involved Esposito Pamela, Director, that happened on Sep 17 ’24 when 13500.0 shares were sold. Director, PAMELA ESPOSITO completed a deal on Sep 17 ’24 to buy 13500.0 shares. Meanwhile, Director Albers Jeffrey W. sold 5000.0 shares on Aug 26 ’24.
